Maria Ines Brito Morgado

Ms. Maria Ines Brito Morgado

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EBElena Gatt Bonanno
Elena Gatt Bonanno
TFTeodora Figueiredo
Teodora Figueiredo
IMInês Mimoso
Inês Mimoso
MMMaria Ines Brito Morgado
Maria Ines Brito Morgado
JCJoana Carrilho
Joana Carrilho
Elisio CostaElisio Costa
Elisio Costa
Polypharmacy, a common condition among the older population, is associated with adverse outcomes, including higher mortality, falls and hospitalization rates, adverse drug reactions, drug–drug interactions, medication nonadherence, and consequently increased healthcare costs. Background/Objectives: This study aims to explore the prevalence of polypharmacy and its associated factors among older adults across 27 European countries and Israel. Methods: In this cross-sectional analysis, we used data from participants aged 65 years or older from Wave 9 of the Survey of Health, Aging, and Retirement in Europe (SHARE) database. The variables studied were classified into the following categories: sociodemographic, behavioral factors, physical functioning, physical health, mental health, and living conditions. Results: Our results showed an overall prevalence of polypharmacy of 36.2%, ranging from 25.0 to 51.8%. Slovenia, Greece, and Switzerland were the countries with the lowest prevalence, whereas Portugal, Israel, and Poland were the countries where the prevalence of polypharmacy was the highest. Polypharmacy was shown to be associated with variables from all categories. Conclusions: Polypharmacy is a highly prevalent condition in the older population. Identification of variables associated with polypharmacy, such as those identified in this study, is important to identify and monitor older groups, which are most vulnerable to polypharmacy. Interventions designed to reduce polypharmacy should consider these associations.

12 November 2025 in Sensors
Verified
Journal Article
Open access
PDF file
IMInês Mimoso
Inês Mimoso
Marcelo Brites-PereiraMarcelo Brites-Pereira
Marcelo Brites-Pereira
LALeovaldo da Silva Alcântara
Leovaldo da Silva Alcântara
MMMaria Ines Brito Morgado
Maria Ines Brito Morgado
Gualter MorgadoGualter Morgado
Gualter Morgado
Elisio CostaElisio Costa
Elisio Costa
Smart furniture represents a growing field that integrates Internet of Things (IoT), embedded systems and assistive technologies, yet lacks a comprehensive synthesis of its components and applications. This PRISMA-guided systematic review analysed 35 studies published between 2014 and 2024, sourced from PubMed, Web of Science and Scopus. The included studies presented prototypes of smart furniture that used IoT, sensors or automation. The focus was on extracting data related to technological configurations, functional uses, validation methods, maturity levels and commercialisation. Three technological pillars emerged, data collection (n = 31 studies), transmission/processing (n = 30), and actuation (n = 22), often combined into multifunctional systems (n = 14). Health monitoring was the dominant application (n = 15), followed by environmental control (n = 8) and assistive functions for older adults (n = 8). Validation methods varied; 37% relied solely on laboratory testing, while 20% only involved end-users. Only one solution surpassed Technology Readiness Level (TRL) 7 and is currently on the market. Current research remains pre-commercial, with gaps in AI integration, long-term validation, and participatory design. Smart furniture shows promise for healthcare and independent living, but requires standardised evaluation, ethical data practices, and co-creation to achieve market readiness.